Wolffian duct cell tumor
Background. Wolffian duct cell tumor is a little studied and rarely found neoplasm. No more than 100 cases of this tumor have been described in the world literature. The tumor develops due to disorders in the process of embryogenesis. In the female fetus, the Wolffian ducts are known to undergo involution, whereas the low level of anti-Müllerian hormone allows the Müllerian duct to develop. However, when differentiation of female genital organs is impaired, the fetus develops neoplasms from the rudiments of the Wolffian duct. According to the WHO Classification of Tumors of Female Reproductive Organs, the neoplasm is presently called Wolffian duct cell tumor and is generally detected in the broad ligament of the uterus, fallopian tubes, mesosalpinx, and ovary. There have been single case reports of retroperitoneal Wolffian duct cell tumor in the lateral channel of the abdominal cavity. There are no clinical practice guidelines for the treatment of Wolffian duct cell tumor; therefore, a description of clinical cases of this rare tumor is of interest.Meshkova M.A., Mukhtarulina S.V., Goeva N.S., Volchenko N.N., Novikova E.G., Rubtsova N.A., Vostrov A.N.
Case report. This paper describes a clinical case of a tumor of Wolffian origin concurrent with stage IB1 cervical cancer in a 45-year-old woman. It shows the features of clinical and instrumental examinations. A morphological study plays a key role in the diagnosis of an ovarian tumor. An immunohistochemical study is a specified diagnostic method, which reveals no expression with antibodies to Inhibin, Vimentin, Calretinin, Chromogranin, CD-99, CD-10, WT-1, and estrogen receptors. The tumor cells focally expressed SK-7, EMA, and p-53, which suggested that the tumors of Wolffian origin are immunologically non-specific. The data available in the literature show that no expression with anti-CD-56 antibodies may indicate the benign course of the tumor.
Conclusion. The clinical case under discussion shows that in the morphological pattern of the tumor, there are no necrotic areas or signs of invasive growth into the capsule; a low mitotic activity was found. In this connection, the tumor was regarded as apparently benign. It is recommended that the patient be followed up.
Keywords
Wolffian duct
Wolffian duct cell tumor
immunohistochemcal study
ovarian tumor
References
- Karminejad M., Scully R. Female adnexal tumor of probable Wolffian origin: a distinct pathologic entity. Cancer. 1973; 31(3): 671-7.
- Rosen С., Reardon E., Shyu S., Terhune J., Saats P., Ioffe O., Kavic S. Wolffian tumor (female adnexal tumor of Wolffian origin) presenting as a pelvic side wall mass: Report of a case. SAGE Open Med. Case Rep. 2019; 7: 2050313X19839534. https://dx.doi.org/10.1177/2050313X19839534.
- Liu L., Fang Q., Xing Y. Female adnexal tumor of probable Wolffian origin arising from mesosalpinx: A case report and review. J. Obstet. Gynaecol. Res. 2018; 44(9): 1859-63. https://dx.doi.org/10.1111/jog.13704.
- Hong S., Cui J., Li L., Buscema J., Liggins C., Zheng W. Malignant female adnexal tumor of probable Wolffian origin: case report and literature review. Int. J. Gynecol. Pathol. 2018; 37(4): 331-7. https://dx.doi.org/10.1097/PGP.0000000000000422.
- Дубова Е.А., Павлов К.А., Лищук С.В., Тертычный А.С., Бахвалова А.А., Брюнин Д.В. Опухоль из клеток вольфова протока: клиническое наблюдение и обзор литературы Альманах клинической медицины. 2018; 46(4): 374-8. [Dubova E.A., Pavlov К.A., Lishchuk S.V., Tertychnyi A.S., Bakhvalova A.A., Bryunin D.V. Wollfian tumor: a case report and a literature review. Almanac of Clinical Medicine. 2018; 46(4): 374-8. (in Russian)]. https://dx.doi.org/10.18786/2072-0505-2018-46-4-374-378.
- Qiu T., Teng Y., Tong J., Tao W., Xu L. Recurrent female adnexal tumor of probably Wolffian origin: A case report. Taiwan. J. Obstet. Gynecol. 2017; 56(3): 382-4. https://dx.doi.org/10.1016/j.tjog.2016.12.017.
- Cossu A., Casula M., Paliogiannis P., Tanda F., Palomba G., Sini M.C. et al. Female Adnexal Tumors of Probable Wolffian origin (FATWO): a case series with next-generation sequencing mutation analysis. Int. J. Gynecol. Pathol. 2017; 36(6): 575-81. https://dx.doi.org/10.1097/PGP.0000000000000368.
- Moro F., Pozzati F., Di Legge A., De Blasis I., Scambia G., Testa A.C. Adnexal tumor of probable Wolffian origin arising from retroperitoneal space. Ultrasound Obstet. Gynecol. 2017; 49(6): 807-8. https://dx.doi.org/10.1002/uog.17226.
- Kwon M.J., Yun M.J., Kim M.K. A female adnexal tumor of probable Wolffian origin showing positive O-6-methylguanine-DNA methyltransferase methylation. Obstet. Gynecol. Sci. 2016; 59(4): 328-32. https://dx.doi.org/10.5468/ogs.2016.59.4.328.
- Nann D., Gahlen S., Keul H.G., Voigt H.J., Fend F., Staebler A. Tumor of the mesosalpinx with unclear differentiation. Pathologe. 2016; 37(1): 84-7. https://dx.doi.org/10.1007/s00292-015-0128-6.
- Gupta A.K., Srinivasan R., Nijhawan R. Female adnexal tumor of probable Wolffian origin. Indian J. Pathol. Microbiol. 2014; 57(4): 620-2. https://dx.doi.org/10.4103/0377-4929.142703.
- Liu R.Q., Zhang Z.H., Pan M.H., Zhang Z.H., Fan Q.H. Wolffian adnexal tumor: report of a case. Zhonghua Bing Li Xue Za Zhi. 2013; 42(7): 476-7.
- Rey R., Picard J.Y. Embryology and endocrinology of genital development. Baillieres Clin. Endocrinol. Metab. 1998; 12(1): 17-33.
- Kurman R.J., Carcangiu M.L., Herrington C.S., Young R.H., eds. WHO Classification of tumours of female reproductive organs. Revised 4th ed. Lyon: IARC Press; 2014. 312p.
- Tavassoli F.A., Devilee P., eds. World Health Organization Classification of tumors. Pathology and genetics of tumours of the breast and family genital organs. Lyon: IARC Press; 2003: 212-3.
- Brocard H., Renault P., Grivaux M., Pichard R. Malignant retroperitoneal tumor of the wolffian epithelioma type. Sem. Hop. 1950; 26(72): 3773-6.
- Heatley M.K. Is female adnexal tumour of probable wolffian origin a benign lesion? A systematic review of the English literature. Pathology. 2009; 41(7): 645-8. https://dx.doi.org/10.3109/00313020903273084.
- Hong S., Cui J., Li L., Buscema J., Liggins C., Zheng W. Malignant female adnexal tumor of probable Wolffian origin: case report and literature review. Int. J. Gynecol. Pathol. 2018; 37(4): 331-7. https://dx.doi.org/10.1097/PGP.0000000000000422.
- Heller D.S., Kadire B., Cracchiolo B. Malignant female adnexal tumor of probable Wolffian origin: a case report. J. Reprod. Med. 2011; 56(3): 175-7.
- Liu Y. Metastatic female adnexal tumor of possible wolffian origin (FATWO) of the appendix demonstrated by FDG PET/CT: the first reported case. Clin. Nucl. Med. 2011; 36(2): 136-7. https://dx.doi.org/10.1097/RLU.0b013e318203bc77.
- Höckel M. Total mesometrial resection – Author’s reply. Lancet Oncol. 2005; 6(12): 919-20. https://dx.doi.org/10.1016/S1470-2045(05)70441-1.
- Steed H., Oza A., Chapman W.B., Yaron M., De Petrillo D. Female adnexal tumor of probable wolffian origin: a clinicopathological case report and a possible new treatment. Int J Gynecol Cancer. 2004; 14(3): 546-50.
- Sakai K., Abiko N., Kondoh E., Yamaguchi K., Minamiguchi S. Two cases of Wolffian tumor with novel magnetic resonance imaging findings reflecting characteristic pathology. J Obstet Gynaecol Res. 2016; 42: 1046-51.
- Mathevon J. Metastatic development of a wolffian tumor of the ovary; seminoma of the ovary with survival for more than five years. Lyon Chir. 1951; 46(6): 759-61.
- Colson P. Wolffian tumor of the ovary; uterine and vaginal metastases. Lyon Chir. 1950; 45(6): 752-3.
- Sivridis E., Giatromanolaki A., Koutlaki N., Anastasiadis P. Malignant female adnexal tumor of probable Wolffian origin: criteria of malignancy. Histopathology. 2005; 46(6): 716-8. https://dx.doi.org/10.1111/j.1365-2559.2005.02035.x.
- Nakayama K., Miura H., Fujiwaki R., Manabe A. Malignant female adnexal tumor of Wolffian origin (FATWO) positive for CD56: a possible diagnostic role for the biomarker. Eur. J. Gynaecol. Oncol. 2014; 35(5): 580-3.
- Wakayama A., Matsumoto H., Aoyama H., Saio M., Kumagai A., Ooyama T., Inamine M., Aoki Y. Recurrent female adnexal tumor of probable Wolffian origin treated with debulking surgery, imatinib and paclitaxel/carboplatin combination chemotherapy: A case report. Oncol. Lett. 2017; 13(5): 3403-8. https://dx.doi.org/10.3892/ol.2017.5874.
Received 31.12.2019
Accepted 07.02.2020
About the Authors
Svetlana V. Muhtarulina, PhD, Head of the Oncogynecology department of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia. Tel.: +7(916)148-27-13. E-mail: svmukhtarulina@yandex.ru. 125284, Russia, Moscow, Vtoroi Botkinski pr., 3.Elena G. Novikova, PhD, professor, Honoured Science Worker of Russian Federation, Deputy Head of the Oncogynecology department of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia. Tel.: +7(916)126-28-38. E-mail: egnov@bk.ru.
125284, Russia, Moscow, Vtoroi Botkinski pr., 3.
Maria A. Meshkova, Clinical Resident of 1-st year of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia.
Тel.: +7(937)065-81-20. E-mail: mari.meshkova.95@mail.ru. 125284, Russia, Moscow, Vtoroi Botkinski pr., 3.
Natalia S. Goeva, pathologist of the Pathologic department of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia. Тel.: +7(903)139-77-91. E-mail: natalia.lisago@yandex.ru. 125284, Russia, Moscow, Vtoroi Botkinski pr., 3.
Nadezhda N. Volchenko, PhD, professor, Head of the Pathologic department of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia. Тel.: +7(916)138-85-22, E-mail: rna17@yandex.ru. 125284, Russia, Moscow, Vtoroi Botkinski pr., 3.
Natalia A. Rubtsova, PhD, Head of the Radiation diagnostics department of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia. Тel.: +7(916)138-85-22, E-mail: rna17@yandex.ru. 125284, Russia, Moscow, Vtoroi Botkinski pr., 3.
Alexandr N. Vostrov, cms, senior research specialist of the Department of Ultrasound diagnostics of P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of Russia. Тel.: +7(903)711-40-80, E-mail: alexander-v65@yandex.ru. 125284, Russia, Moscow, Vtoroi Botkinski pr., 3.
For reference: Meshkova M.A., Mukhtarulina S.V., Goeva N.S., Volchenko N.N., Novikova E.G., Rubtsova N.A., Vostrov A.N. Wolffian duct cell tumor.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 6: 152-158 (in Russian)
https://dx.doi.org/10.18565/aig.2020.6.152-158